Clinical Trial Update: Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial update investigating anlotinib combined with chemotherapy and neoadjuvant therapy for hormone receptor-positive, HER-2 negative breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Xijing Hospital | Conditions: Breast Cancer Stage II | Phase 2 | Status: UNKNOWN